Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress
CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...